Form D · Pharmaceuticals

Sage Therapeutics, Inc.

Cambridge, MA · CIK 0001597553

Offering snapshot reported Jan 15, 2021 · SEC filing

Reported sold
$650M
Offering amount: $650M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 31, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 15, 2021Initial$649,986,998No comparison1SEC filing
Mar 24, 2014Initial$38,000,000No comparison15SEC filing
Jan 21, 2014Initial$10,000,000No comparison3SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-386553

Source: Form D, filed Jan 15, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Elizabeth Barrett Director
Michael Cloonan Executive
Michael F. Cola Director
Anne Marie Cook Executive
James F. Frates Director
Geno Germano Director
George Golumbeski Director
Barry Greene Director, Executive
Kimi Iguchi Executive
Jeffery M. Jonas Director, Executive
Jeffrey M. Jonas Director, Executive
Stephen J. Kanes Executive
Robert T. Nelsen Director
Steven Paul Director
Albert J. Robichaud Executive
Kevin P. Starr Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
215 First Street
Cambridge, MA, 02142